Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

Table 2

Clinical efficacy of checkpoint inhibitors in relapsed/refractory HL.

Drug	Ph	Target	N	ORR (%)	CR (%)	PR (%)	SD (%)	OS	PFS	Ref
Nivolumab	I	Anti-PD-1	23	87	17	70	13		2 years, 86%	10
Nivolumab	II	Anti-PD-1	80	66	9	58	NR	6 m 77%	6 m, 77%	11
Nivolumab+	I	Anti-PD-1	31	74	19	55	10	NR	NR	13
Nivolumab + BV	I	Anti-PD-1	10	100	63			NR	4 m, 100%	14
Pemolizumab	Ib	Anti-PD-1	31	58	19	12	23	NR	11.4	15
Pemolizumab	II	Anti-PD-1	210	65–68	22–29					16
Ipilimumab	I	Anti-CTLA-4	12	67	42				0.74 years	19

HL: Hodgkin lymphoma; Ph: phase; N: number of patients; m: month; ORR: overall response rate; CR: complete response; PR: partial response; SD: stable disease; OS: overall response; PFS: progression-free survival; Ref: reference; R/R: relapsed and refractory; BV: brentuximab vedotin; NR: not reached.